About a year after announcing a tobacco strategy involving nicotine levels in cigarettes and other related measures to reduce tobacco use among Americans, the U.S. Food and Drug Administration (FDA) said it will take another look at the process by which it evaluates new tobacco products and how it approves them for marketing and sale in the United States.

The current process, involving what many in the industry describe as an onerous and expensive premarket tobacco application (PMTA) and a modified-risk tobacco product application (MRTPA), will undergo an agency review that will include a public comment period and a two-day public meeting from Oct. 22-23 at the FDA’s headquarters in Silver Spring, Md.

Through its website and FDA blog post, the agency detailed its next steps.

Illustration by CSP